Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study

Kobayashi, Tomoko, Iwama, Shintaro, Yasuda, Yoshinori, Okada, Norio, Tsunekawa, Taku, Onoue, Takeshi, Takagi, Hiroshi, Hagiwara, Daisuke, Ito, Yoshihiro, Morishita, Yoshiaki, Goto, Motomitsu, Suga, Hidetaka, Banno, Ryoichi, Yokota, Kenji, Hase, Tetsunari, Morise, Masahiro, Hashimoto, Naozumi, Ando, Masahiko, Kiyoi, Hitoshi, Gotoh, Momokazu, Ando, Yuichi, Akiyama, Masashi, Hasegawa, Yoshinori, Arima, Hiroshi·2018·Journal of the Endocrine Society
DOI 10.1210/js.2017-00432

Cited by (203)

Items 101–200 of 203

  1. Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events
    Tomoko Kobayashi, Shintaro Iwama, Hiroshi Arima · 2023 · Endocrine Journal
  2. Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma
    Zena N. Willsmore, Lucy H. Booth, Akshay Jatin Patel, Ashley Di Meo, Ioannis Prassas, Jitesh Chauhan, Yin Wu, Amanda Fitzpartick, Katie Stoker, Matthaios Kapiris et al. · 2025 · Journal for ImmunoTherapy of Cancer
  3. Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma
    Wedad Rahman, Anna T. Conley, Kristi D. Silver · 2020 · BMJ Case Reports
  4. Endocrine Dysfunction From Immune Checkpoint Inhibitors: Pearls and Pitfalls in Evaluation and Management
    Anupam Kotwal, Jordan E. Perlman, Whitney Sears Goldner, Alissa Marr, Jennifer Sophie Mammen · 2023 · JCO Oncology Practice
  5. Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study
    Yoko Ueba, Ichiro Yamauchi, Takuro Hakata, Haruka Fujita, Kentaro Okamoto, Kaori Ikeda, Yohei Ueda, Toshihito Fujii, Daisuke Taura, Nobuya Inagaki · 2022 · Endocrine Journal
  6. Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors
    Fabiana Pani, Yoshinori Yasuda, Sylvie T. Rousseau, Kevin Christian Bermea, Solmaz Roshanmehr, Rulin Wang, Srinivasan Yegnasubramanian, Patrizio Caturegli, Luigi Adamo · 2022 · Journal for ImmunoTherapy of Cancer
  7. Endocrine dysfunctions during treatment of immune-checkpoint inhibitors
    Hidefumi Inaba, Hiroyuki Ariyasu, Hisako Okuhira, Yuki Yamamoto, Hiroaki Akamatsu, Masahiro Katsuda, Masatoshi Jinnin, Isao Hara, Takashi Akamizu · 2018 · Trends in Immunotherapy
  8. Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study
    Tomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, Tetsushi Izuchi, Koji A. O. Suzuki, Koki Otake, Yoshinori Yasuda, Masahiko Ando, Takeshi Onoue, Takashi Miyata et al. · 2024 · Cancer Immunology Immunotherapy
  9. Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC)
    Adila Abulizi, Guang-Peng Yan, Qian Xu, Reyihanguli Muhetaer, Shihan Wu, Kudelaiti Abudukelimu, Xi Chen, Chengjiang Liu, Jun Li · 2024 · Scientific Reports
  10. Les dysthyroïdies sous immunothérapie anti-cancéreuse
    Christine Cugnet Anceau, Juliette Abeillon, Denis Maillet, Françoise Borson‐Chazot, Emmanuel Disse · 2019 · Bulletin du Cancer
  11. Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer
    Masakatsu Nakamura, Toshimi Otsuka, Ranji Hayashi, Tomoe Horita, Masafumi Ota, Naoko Sakurai, Hikaru Takano, Tasuku Hayashi, Motona Kumagai, Sohsuke Yamada et al. · 2020 · Internal Medicine
  12. Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms
    Jeroen M. K. de Filette, Stéphanie André, Lynn De Mey, Sandrine Aspeslagh, Rafik Karmali, Bart J.R. Van der Auwera, Bert Bravenboer · 2022 · BMC Endocrine Disorders
  13. Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival
    Mario Giovanni Chilelli, Carlo Signorelli, Julio Rodrigo Giròn Berrìos, Angelo Onorato, Fabrizio Nelli, Agnese Fabbri, Francesca Primi, Eleonora Marrucci, Antonella Virtuoso, Marta Schirripa et al. · 2022 · Cancer Diagnosis & Prognosis
  14. Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer
    Yuji Shibata, Shuji Murakami · 2020 · Expert Opinion on Drug Safety
  15. Correlation between different levels of thyroid autoantibodies and immune checkpoint inhibitor-associated thyroid dysfunction
    Yanyan Jiao, Meihua Xu, Xiaopang Rao · 2025 · Frontiers in Endocrinology
  16. Risk factors for immune-related adverse effects during CPI therapy in patients with head and neck malignancies – a single center study
    Frederic Jungbauer, Annette Affolter, Christoph Brochhausen, Anne Lammert, Sonja Ludwig, Kirsten Merx, Nicole Rotter, Lena Huber · 2024 · Frontiers in Oncology
  17. Immune-Related Thyroiditis as a Predictor for Survival in Metastatic Renal Cell Carcinoma
    Shira Sagie, Moran Gadot, Meital Levartovsky, Hadas Gantz Sorotsky, Raanan Berger, Michal Sarfaty, Ruth Percik · 2022 · Cancers
  18. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer
    Ako Gannichida, Yusuke Nakazawa, Akira Kageyama, Hirofumi Utsumi, Kazuyoshi Kuwano, Takashi Kawakubo · 2022 · World Journal of Clinical Oncology
  19. Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade
    Ayana Yamagami, Shintaro Iwama, Tomoko Kobayashi, Xin Zhou, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Tetsushi Izuchi, Masahiko Ando, Takeshi Onoue et al. · 2024 · Endocrine Journal
  20. Immunologic adverse events from immune checkpoint therapy
    Michael D. Richter, Grant C. Hughes, Sarah H. Chung, Mary Ezeanuna, Namrata Singh, John A. Thompson · 2020 · Best Practice & Research Clinical Rheumatology
  21. Risk factors and outcomes of thyroid immune-related adverse events following PD-1/PD-L1 inhibitors treatment in a large tertiary Chinese center
    Wenwen Gong, Erhan Zheng, Minchao Liu, Yu Han, Zhaohui Lyu, Qinghua Guo · 2025 · BMC Endocrine Disorders
  22. Development of pituitary dysfunction and destructive thyroiditis is associated with better survival in non-small cell lung cancer patients treated with programmed cell death-1 inhibitors: a prospective study with immortal time bias correction
    Koji A. O. Suzuki, Tomoko Kobayashi, Tetsushi Izuchi, Koki Otake, Masahiko Ando, Tomoko Handa, Takashi Miyata, Mariko Sugiyama, Takeshi Onoue, Daisuke Hagiwara et al. · 2024 · Frontiers in Endocrinology
  23. Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study
    Shintaro Iwama, Tomoko Kobayashi, Tetsushi Izuchi, Koji Suzuki, Takanori Murase, Masahiko Ando, Tomoko Handa, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama et al. · 2025 · Endocrinology and Metabolism
  24. Immune Checkpoint Inhibitor-induced Thyroid Disorders: A Single Center Experience
    Poupak Fallahi, Armando Patrizio, Alessandro Antonelli, Silvia Martina Ferrari · 2022 · Current Pharmaceutical Design
  25. Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
    Ichiro Yamauchi, Takuro Hakata, Taku Sugawa, Daisuke Kosugi, Haruka Fujita, Kentaro Okamoto, Yohei Ueda, Toshihito Fujii, Daisuke Taura, Norio Harada et al. · 2023 · Endocrine Journal
  26. Characterizing Thyroid Hormone Replacement, Baseline Thyrotropin, and Survival in Immune Checkpoint Inhibitor–Associated Thyroid Dysfunction
    Duaa Abdallah, Jake N Johnson, Fang Qiu, Whitney Sears Goldner, Apar Kishor Ganti, Anupam Kotwal · 2025 · Thyroid
  27. Dynamic follow-up of the effects of programmed death 1 inhibitor treatment on thyroid function and sonographic features in patients with hepatocellular carcinoma
    Xiaoya Zheng, Heng Xiao, Jian Long, Qiang Wei, Liping Liu, Liping Zan, Wei Ren · 2022 · Endocrine Connections
  28. Thyroid Dysfunction from Treatments for Solid Organ Cancers
    Anupam Kotwal, Donald S.A. McLeod · 2022 · Endocrinology and Metabolism Clinics of North America
  29. Endocrine dysfunctions during treatment of immune-checkpoint inhibitors
    Hidefumi Inaba, Hiroyuki Ariyasu, Hisako Okuhira, Yuki Yamamoto, Hiroaki Akamatsu, Masahiro Katsuda, Masatoshi Jinnin, Isao Hara, Takashi Akamizu · 2020 · Trends in Immunotherapy
  30. Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes
    Sara Salehi Hammerstad, Hanna J. Lee, Yaron Tomer, Mihaela Stefan–Lifshitz · 2025 · Journal of Endocrinological Investigation
  31. Sintilimab-induced diabetes mellitus and thyroid dysfunction in patient with gastric adenocarcinoma: A case report and literature review
    Ying Zan, Yedong Wei, Wenxue Zhang, Xiaolu Gao, Jigang Si · 2025 · Medicine
  32. Endocrine Adverse Events of Immune Checkpoint Inhibitors: A Comprehensive Review
    Remya Rajan, Devika Nandakumar · 2025 · Indian Journal of Endocrinology and Metabolism
  33. Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients—exploratory results from TITAN-RCC
    A Fritzsch, Katharina Leucht, Nadja Röber, Karsten Conrad, Rebecca Rothe, Rebekka Wehner, Ulrike Schumacher, Emilio Esteban, Philippe Barthélémy, Manuela Schmidinger et al. · 2025 · ESMO Open
  34. Pembrolizumab-Induced Thyroid Storm in a Patient With Triple-Negative Breast Cancer
    Sheriff Mohammed, Eun Young Park, Reda Asad, Shourya Tadisina · 2025 · AACE Endocrinology and Diabetes
  35. Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors
    Nicola Marrano, Mariangela Caporusso, Carlo Ganini, Andrea Borraccino, Angelo Cignarelli, Sebastio Perrini, Luigi Laviola, Camillo Porta, Francesco Giorgino, Annalisa Natalicchio · 2025 · Journal of Endocrinological Investigation
  36. A case of hypophysitis after COVID-19 vaccination with a detection of anti-pituitary antibody, with review of literature
    Chika Kyo, Tomoko Kobayashi, Shintaro Iwama, Rieko Kosugi, Fumikazu Sawabe, Ryo Hayafusa, Yuki Sakai, Tatsuo Ogawa, Masato Kotani, Tatsuhide Inoue et al. · 2024 · Endocrine Journal
  37. Immunotherapy: A Case Series
    Tuong Vi Do, Mythili kanthi Gudipati, Subramanya Shyam Ganti, Jayaramakrishna Depa, Kamlesh P. Sajnani · 2021 · Cureus
  38. Lesions in endocrine glands as a complication of immunotherapy in the practice of oncologist
    Nurana F. Nuralieva, Ekaterina Anatol'evna Troshina, Galina Afanas'evna Mel'nichenko · 2019 · Clinical and experimental thyroidology
  39. RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies
    Rena M. Pollack, Joshua Stokar, Natan Lishinsky-Fischer, Irina Gurt, Naomi Kaisar-Iluz, Merav E. Shaul, Zvi Gregorio Fridlender, Rivka Dresner–Pollak · 2023 · International Journal of Molecular Sciences
  40. T3 and T4 autoantibodies: emerging biomarkers for evaluating thyroid disorders
    Jiameng Liu, Chaoming Mao, Xueqian Mao, Xi Wang, Tingting Zheng, Liyang Dong, Yufei Mao · 2025 · Frontiers in Endocrinology
  41. Increased risk of hyperthyroidism induced by immune checkpoint inhibitors in patients with existing or prior Graves’ disease: a nested prospective cohort study with propensity score matching
    Koji A. O. Suzuki, Tomoko Kobayashi, Tetsushi Izuchi, Takanori Murase, Masahiko Ando, Tomoko Handa, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara et al. · 2025 · Frontiers in Endocrinology
  42. Endocrine-Related Adverse Conditions in Pediatric Patients Treated with Immune Checkpoint Inhibition for Malignancies
    Shlomit Shalitin · 2024 · Hormone Research in Paediatrics
  43. Unexpected cure of a toxic nodule in a multinodular goiter induced by immune checkpoint inhibitors: a case report
    H. Dupuis, E. Merlen, Arnaud Jannin, Philippe Jamme, Alexandre Fagart, Marie‐Christine Vantyghem, Miriam Ladsous · 2022 · European Thyroid Journal
  44. Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective
    Alejandra Flores-Chávez, Pilar Brito‐Zerón, Soledad Retamozo, Samuel Bitoun, Benjamin A. Fisher, David F. L. Liew, Karijn P.M. Suijkerbuijk, Katerina Chatzidionysiou, Maria Eugenia Suarez-Almazor, Olivier Lambotte et al. · 2022 · Critical Reviews in Immunology
  45. Neoadjuvant immunotherapy plus chemotherapy in high altitude natives with resectable esophageal squamous cell carcinoma in Tibet
    Xizhao Sui, Duoji Danzeng, Ping Ni, Jiayi Geng, Pingcuo Gesang, Zhaxi Renqing, Yuling Wei · 2024 · Asian Journal of Surgery
  46. A Case of Thyroid Dysfunction and Isolated Adrenocorticotropin Deficiency after Nivolumab Therapy for Malignant Melanoma
    Kosuke Nishio, Yosuke Okada, Akira Kurozumi, Yoshiya Tanaka · 2021 · Journal of UOEH
  47. Hypothyroidism induced by immune checkpoint inhibitors combined with antiangiogenic agents is associated with higher body mass index
    Xinyue Wang, Xiuqiong Chen, Jing Zhou, Richeng Jiang · 2023 · Journal of Thoracic Disease
  48. Clinical Significance of Thyroid Autoantibodies in Differential Diagnosis and Predicting the Course of Programmed Cell Death Protein-1 Inhibitor-Induced Thyroid Dysfunction
    Li Li, Xiaoxia Ding, Xihui Zhang, Shuangming Kong, Ming Chen · 2024 · Endocrine Practice
  49. Changes in thyroid hormone levels indicate immunotherapy efficacy in gastric cancer
    Min Xiao, Lan Qian, Qiu Zhao, Jian Ma, Qianxiao Li, Qian Liu, Zhiyan Bi · 2025 · Oncology Letters
  50. Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
    Tomoko Kobayashi, Shintaro Iwama, Eri Sugiyama, Shohei Koyama, Tetsushi Izuchi, Koji Suzuki, Takanori Murase, Masahiko Ando, Hidefumi Inaba, Hiroki Izumi et al. · 2026 · Cancer Immunology Research
  51. Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee
    Fatemeh Ardeshir‐Larijani, Leanne Ashrafian, Marco Chiappetta, Daniel Mansilla, Alessandro Wasum Mariani, Jessica Menis, Andreas Rimner, Aparna Sharma, Małgorzata Szołkowska, Swasthik Upadhya et al. · 2026 · Journal of Thoracic Oncology
  52. Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series
    Luigi Liguori, Angelo Luciano, Giovanna Polcaro, Alessandro Ottaiano, Marco Cascella, Francesco Perri, Stefano Pepe, Francesco Sabbatino · 2023 · Biomedicines
  53. Atypical Clinical Courses of Graves' Disease Confound Differential Diagnosis of Hyperthyroidism
    Yuji Yamaguchi, Fumitaka Okajima, Hitoshi Sugihara, Masato Iwabu, Naoya Emoto · 2023 · Journal of Nippon Medical School
  54. Development of Overt Thyroid Dysfunction and Antithyroid Antibodies with Anti-PD-1 Use in Various Cancers Is Associated with Favorable Survival
    Jochen H. Lorch · 2020 · Clinical Thyroidology
  55. Relationship of Hypothyroidism and Immune Response to Pegylated IL-10/nivolumab
    Mary Albrethsen, Justin F. Creeden, Susan M. Morand, Joseph M DeBiase, Brittany M. Berry, Laura Stanbery, Gerald M. Edelman, John J. Nemunaitis · 2020 · Immunotherapy
  56. The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists
    Maria V. Deligiorgi, Dimitrios T. Trafalis · 2022 · Expert Review of Clinical Pharmacology
  57. Complete remission in PD-L1 high expression advanced gastric cancer patient with PD-L1 immunotherapy and chemotherapy integration treatment strategy: a case report
    Xiaopeng Yu, Wenwen Zhao, Qingqing Feng, Tian Jin, Lili Zhao, Jun Xiao, Hongmei Wei · 2025 · Frontiers in Oncology
  58. Baseline thyroid function and treatment-emergent thyroid dysfunction predict pathological response and survival after neoadjuvant PD-1 inhibitor plus platinum-based chemotherapy in locally advanced gastric and gastroesophageal junction adenocarcinoma: a multicenter cohort study
    Zhiqiang Wang, Jie Zheng, Le Wang, Ning Meng, Zhenjiang Guo, Xiaolong Li, Kaixuan Gao, Tao Zheng · 2026 · Frontiers in Endocrinology
  59. Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies
    Annu Susan George, Cornelius James Fernandez, Dilip Eapen, Joseph M Pappachan · 2021 · touchREVIEWS in Endocrinology
  60. Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients
    Adi Horesh, Rena M. Pollack, Hovav Nechushtan, Rivka Dresner–Pollak, Tzahi Neuman · 2023 · Pathology & Oncology Research
  61. Serologic predictors of thyroid immune-related adverse events during immune checkpoint inhibitors therapy: a retrospective cohort study
    Анастасия Андреевна Глибка, Natalya Valentinovna Mazurina, К. А. Саранцева, Галина Юрьевна Харкевич, Волконский Михаил Викторович, Alina R. Elfimova, Ekaterina Anatol'evna Troshina · 2024 · Almanac of Clinical Medicine
  62. Involvement of Neutrophil-lymphocyte Ratio in Nivolumab Therapy-induced Hypothyroidism
    Yusuke Nakazawa, Ako Gannichida, Akira Kageyama, Hirofumi Utsumi, Kazuyoshi Kuwano, Takashi Kawakubo · 2020 · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
  63. Expert system verification and validation for nuclear power industry applications
    Joseph A. Naser · 1990 · Transactions of the American Nuclear Society
  64. Schilddrüsenfunktionsstörungen unter Immuncheckpoint-Inhibitor-Therapie
    Verena Theiler‐Schwetz, Christian Trummer, Erika Richtig, Georg Richtig, Stefan Pilz · 2020 · Journal für Klinische Endokrinologie und Stoffwechsel
  65. 免疫チェックポイント阻害薬の副作用 ～糖尿病・内分泌代謝領域～
    田中 利明 · 2020 · 杏林医学会雑誌
  66. A case of simultaneous double cancer of oral malignant melanoma and lung adenocarcinoma with nivolumab-induced destructive thyroiditis
    Tomohiro TAKAYAMA, Kaoru Murakami, Chikashi Minemura, Ryota YOSHIDOME, Koji Yamamura, Hidetaka Yokoe · 2020 · Japanese Journal of Oral & Maxillofacial Surgery
  67. History of Radiation to the Neck Increases the Risk of Denovo Thyroid Dysfunction after Receiving Immune Checkpoint Inhibitors
    Koosha Paydary, Muhammad Zain Farooq, Ankit Mangla · 2020 · Endocrines
  68. Optimizing Care for Patients With Adverse Events From Immunotherapeutics
    Kelsey Sheehan, Christina C. Price, Navid Hafez · 2020 · The Cancer Journal
  69. Endokrynologiczne powikłania nowych terapii przeciwnowotworowych
    Michał Miner, Michał Elbaum, Aleksandra Jawiarczyk-Przybyłowska, Eliza Kubicka · 2021 · Postępy Higieny i Medycyny Doświadczalnej
  70. Autoanticuerpos: una manifestación de los eventos adversos inmunológicos de la inmunoterapia en cáncer
    Alba Lucía Cómbita · 2021 · Revista Colombiana de Reumatología
  71. Autoantibodies: A manifestation of immune related adverse events of cancer immunotherapy
    Alba Lucía Cómbita · 2022 · Revista Colombiana de Reumatología (English Edition)
  72. 4) Immune-related Adverse Events in Endocrine Organs Induced by Immune Checkpoint Inhibitors
    Hiroshi Arima, Tomoko Kobayashi, Shintaro Iwama · 2019 · Nihon Naika Gakkai Zasshi
  73. Nivolumab
    2018 · Reactions Weekly
  74. Immune Checkpoint Inhibitor–Associated Thyroiditis Risk Lurking in the Ultrasound
    Samantha Sovich, Melissa G. Lechner · 2022 · Clinical Thyroidology
  75. Increased Risk of Thyroid Dysfunction with Combination PD-1 and CTLA-4 Blockade, Even in the Absence of Positive Thyroid Antibodies
    Anupam Kotwal · 2022 · Clinical Thyroidology
  76. Dermatomyositis Triggered by Immune Checkpoint Inhibitors. Three Additional Cases and a Review of the Literature
    Néstor López-Guerra, Ana Matas-García, Laura Serra‐García, Daniel Morgado‐Carrasco, Joan Padrosa, Ibán Aldecoa, Yaiza Duque-Jaimez, Raquel Aránega, Pedro Moreno, Judith Cantó et al. · 2022 · SSRN Electronic Journal
  77. Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy
    Aikaterini Lavrentaki, Georgia Ntali · 2023 · Springer eBooks
  78. Endocrinopathies Associated with Immune Checkpoint Inhibitors
    Irena Druce · 2023 · Canadian Diabetes & Endocrinology Today
  79. The Therapeutic Potential of Stem Cells-Conditioned Media on Histologic Changes of Immune Checkpoints Inhibitor Pembrolizumab on Rats Thyroid Gland
    Eman A. Mohamed, Enas G. Abd Allah, Samaa M. El‐Mahroky · 2022 · Journal of Medical Histology/Journal of Medical Histology
  80. Research Advances of Immune Checkpoint Inhibitors Related Endocrine Adverse Events
    晶晶 王 · 2024 · Advances in Clinical Medicine
  81. Immuntherapie mit Checkpointinhibitoren und schilddrüsentypische Komplikationen
    Barbara Kreppel · 2024 · Angewandte Nuklearmedizin
  82. A Case Report and Literature Review of Hypothyroidism Caused by Pembrolizumab
    慧萍 贾 · 2024 · Advances in Clinical Medicine
  83. Immuncheckpointinhibitoren bei Autoimmunerkrankungen
    Claudia Günther, Julian Steininger · 2024 · Im Focus Onkologie
  84. Immuncheckpointinhibitoren bei Autoimmunerkrankungen
    Claudia Günther, Julian Steininger · 2025 · hautnah dermatologie
  85. Further Insights into Immune Checkpoint Inhibitor–Associated Thyroid Dysfunction
    Natalia Genere, Trisha D. Cubb · 2025 · Clinical Thyroidology
  86. 1. Endocrine Dysfunction as Immune-related Adverse Events Induced by Immune Checkpoint Inhibitors
    Shintaro Iwama, Hiroshi Arima · 2024 · Nihon Naika Gakkai Zasshi
  87. Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy
    Aikaterini Lavrentaki, Georgia Ntali · 2025 · Springer eBooks
  88. Additional file 10 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
    Genta, Sofia, Lajkosz, Katherine, N. Yee, Pavlina Spiliopoulou, Heirali, Alya, Aaron Richard Hansen, Siu, Lillian L., Saibil, Sam, Stayner, Lee-Anne, Maryia Yanekina et al. · 2024 · Figshare
  89. Additional file 1 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
    Genta, Sofia, Lajkosz, Katherine, N. Yee, Pavlina Spiliopoulou, Heirali, Alya, Aaron Richard Hansen, Siu, Lillian L., Saibil, Sam, Stayner, Lee-Anne, Maryia Yanekina et al. · 2024 · Figshare
  90. Additional file 7 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
    Genta, Sofia, Lajkosz, Katherine, N. Yee, Pavlina Spiliopoulou, Heirali, Alya, Aaron Richard Hansen, Siu, Lillian L., Saibil, Sam, Stayner, Lee-Anne, Maryia Yanekina et al. · 2024 · Figshare
  91. Additional file 8 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
    Genta, Sofia, Lajkosz, Katherine, N. Yee, Pavlina Spiliopoulou, Heirali, Alya, Aaron Richard Hansen, Siu, Lillian L., Saibil, Sam, Stayner, Lee-Anne, Maryia Yanekina et al. · 2024 · Figshare
  92. Additional file 11 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
    Genta, Sofia, Lajkosz, Katherine, N. Yee, Pavlina Spiliopoulou, Heirali, Alya, Aaron Richard Hansen, Siu, Lillian L., Saibil, Sam, Stayner, Lee-Anne, Maryia Yanekina et al. · 2024 · Figshare
  93. Additional file 3 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
    Genta, Sofia, Lajkosz, Katherine, N. Yee, Pavlina Spiliopoulou, Heirali, Alya, Aaron Richard Hansen, Siu, Lillian L., Saibil, Sam, Stayner, Lee-Anne, Maryia Yanekina et al. · 2024 · Figshare
  94. Additional file 4 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
    Sofia Genta, Lajkosz, Katherine, N. Yee, Pavlina Spiliopoulou, Heirali, Alya, Aaron Richard Hansen, Siu, Lillian L., Saibil, Sam, Stayner, Lee-Anne, Maryia Yanekina et al. · 2024 · Figshare
  95. Additional file 9 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
    Genta, Sofia, Lajkosz, Katherine, N. Yee, Pavlina Spiliopoulou, Heirali, Alya, Aaron Richard Hansen, Siu, Lillian L., Saibil, Sam, Stayner, Lee-Anne, Maryia Yanekina et al. · 2024 · Figshare
  96. Additional file 12 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
    Genta, Sofia, Lajkosz, Katherine, N. Yee, Pavlina Spiliopoulou, Heirali, Alya, Aaron Richard Hansen, Siu, Lillian L., Saibil, Sam, Stayner, Lee-Anne, Maryia Yanekina et al. · 2024 · Figshare
  97. Additional file 2 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
    Genta, Sofia, Lajkosz, Katherine, N. Yee, Pavlina Spiliopoulou, Heirali, Alya, Aaron Richard Hansen, Siu, Lillian L., Saibil, Sam, Stayner, Lee-Anne, Maryia Yanekina et al. · 2024 · Figshare
  98. Additional file 5 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
    Genta, Sofia, Lajkosz, Katherine, N. Yee, Pavlina Spiliopoulou, Heirali, Alya, Aaron Richard Hansen, Siu, Lillian L., Saibil, Sam, Stayner, Lee-Anne, Maryia Yanekina et al. · 2024 · Figshare
  99. Additional file 6 of Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
    Genta, Sofia, Lajkosz, Katherine, N. Yee, Pavlina Spiliopoulou, Heirali, Alya, Aaron Richard Hansen, Siu, Lillian L., Saibil, Sam, Stayner, Lee-Anne, Maryia Yanekina et al. · 2024 · Figshare
  100. Clinical outcomes of cancer patients with pre-existing autoimmune thyroid disease treated with PD-(L)-1 inhibitors: a propensity score methodology with inverse probability of treatment weighting retrospective study
    Yun Shi, Qiuyi Wang, Ziqing Ye, Doudou Chen, Taoyue Yang, Yongyue Wei, Xuqin Zheng · 2026 · Frontiers in Endocrinology